首页> 美国卫生研究院文献>other >Enhanced Apoptotic Cancer Cell Killing after Foscan Photodynamic Therapy Combined with Fenretinide via De Novo Sphingolipid Biosynthesis Pathway
【2h】

Enhanced Apoptotic Cancer Cell Killing after Foscan Photodynamic Therapy Combined with Fenretinide via De Novo Sphingolipid Biosynthesis Pathway

机译:经由De Novo鞘脂生物合成途径联合Fenretinide进行Foscan光动力疗法后增强的凋亡癌细胞杀伤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We and others have shown that stresses, including photodynamic therapy (PDT), can disrupt the de novo sphingolipid biosynthesis pathway, leading to changes in the levels of sphingolipids, and subsequently, modulation of cell death. The de novo sphingolipid biosynthesis pathway includes a ceramide synthase-dependent reaction, giving rise to dihydroceramide, which is then converted in a desaturase-dependent reaction to ceramide. In this study we tested the hypothesis that combining Foscan-mediated PDT with desaturase inhibitor fenretinide (HPR) enhances cancer cell killing. We discovered that by subjecting SCC19 cells, a human head and neck squamous cell carcinoma cell line, to PDT+HPR resulted in enhanced accumulation of C16-dihydroceramide, not ceramide. Concomitantly, mitochondrial depolarization was enhanced by the combined treatment. Enhanced activation of caspase-3 after PDT +HPR was inhibited by FB. Enhanced clonogenic cell death after the combination was sensitive to FB, as well as Bcl2- and caspase inhibitors. Treatment of mouse SCCVII squamous cell carcinoma tumors with PDT+HPR resulted in improved long-term tumor cures. Overall, our data showed that combining PDT with HPR enhanced apoptotic cancer cell killing and antitumor efficacy of PDT. The data suggest the involvement of the de novo sphingolipid biosynthesis pathway in enhanced apoptotic cell killing after PDT+HPR, identify PDT+HPR as a more effective combination than either treatment alone, and that the combination has potential for cancer treatment.
机译:我们和其他人已经表明,包括光动力疗法(PDT) 在内的压力会破坏从头鞘脂的生物合成途径,导致鞘脂水平的改变,随后,调节细胞死亡。从新鞘脂的生物合成途径包括神经酰胺合酶依赖性反应,产生二氢神经酰胺,然后在去饱和酶依赖性反应中转化为神经酰胺。在这项研究中,我们测试了以下假说:将Foscan介导的PDT与去饱和酶抑制剂fenretinide(HPR)结合使用可增强癌细胞的杀伤力。我们发现,通过对人头颈部鳞状细胞癌细胞系SCC19细胞进行PDT + HPR处理,可增强C16-二氢神经酰胺而不是神经酰胺的蓄积。同时,通过联合治疗可以增强线粒体的去极化作用。 PDT + HPR后,caspase-3的增强激活被FB抑制。合并后增加的克隆细胞死亡对FB以及Bcl2-和caspase抑制剂敏感。用PDT + HPR治疗小鼠SCCVII鳞状细胞癌肿瘤可改善长期肿瘤治愈率。总体而言,我们的数据显示,PDT与HPR的结合可增强PDT对凋亡癌细胞的杀伤力和抗肿瘤功效。数据表明,从头鞘糖脂的生物合成途径参与了PDT + HPR后增强的凋亡细胞杀伤,将PDT + HPR鉴定为比任何一种单独治疗更有效的组合,并且该组合具有治疗癌症的潜力。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号